The latest price target for Channel Therapeutics (AMEX:CHRO) was reported by Alliance Global Partners on June 18, 2024. The analyst firm set a price target for $0.00 expecting CHRO to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Channel Therapeutics (AMEX:CHRO) was provided by Alliance Global Partners, and Channel Therapeutics initiated their buy rating.

There is no last upgrade for Channel Therapeutics

There is no last downgrade for Channel Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Channel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Channel Therapeutics was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.

While ratings are subjective and will change, the latest Channel Therapeutics (CHRO) rating was a initiated with a price target of $0.00 to $0.00. The current price Channel Therapeutics (CHRO) is trading at is $0.62, which is out of the analyst’s predicted range.